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Abstract:  Animal models for Parkinson’s disease (PD) are essential for understanding its pathogenesis and for
development and testing of new therapies.  Discoveries of endogenous neurogenesis in the adult mammalian brain give
new insight into the cell-based approach for treatment of neurodegenerative disorders, such as PD.  Although a great
deal of interest has been focused on endogenous neurogenesis in neurotoxin-induced animal models for PD, it still
remains controversial whether neural stem cells migrate into the injured area and contribute to repopulation of depleted
dopaminergic neurons in neurotoxin-injured adult brains.  The purpose of this review is to examine the data available
regarding neurogenesis in neurotoxin-induced animal models of PD.  It is hoped that data from the animal
investigations available in the literature will promote understanding of the neurotoxin-induced animal models for PD.
(J Toxicol Pathol 2009; 22: 101–108)
Key words: animal model, Parkinson’s disease, neurogenesis, MPTP, 6-OHDA
Introduction
Parkinson’s disease (PD) is an age-related degenerative
disorder of the central nervous system.  It is often
characterized by muscle rigidity, tremor, slowing of physical
movement (bradykinesia) and, in extreme cases, loss of
physical movement (akinesia).  The symptoms of PD are
attributed to the loss of pigmented dopamine-secreting
(dopaminergic) neurons in the pars compacta region of the
substantia nigra (SN) and a subsequent striatal deficiency of
dopamine.  Idiopathic PD is also pathologically
characterized by the presence of cytoplasmic neuronal
inclusions, called Lewy bodies, in the affected region of the
brain.  The etiology of the disease has been poorly
understood, and development of novel non-dopaminergic
therapeutic strategies has remmained challenging since
initial description of the disease by James Parkinson in
18171.  Although pharmacological dopamine replacement
strategies provide temporary symptomatic relief, there are at
present no therapeutic methods for halting progressive
neuronal cell loss2.
Animal models are an important tool in elucidating
mechanisms involved in the pathological process and in
investigating new therapeutic strategies for PD.  Currently,
both genetic and toxic models of PD are available, but use of
neurotoxins, such as 6-hydroxydopamine (6-OHDA),
paraquat, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and rotenone, is still the most popular means of
modeling destruction of the nigrostriatal dopaminergic
neurons seen in PD3.  Among these neurotoxins, 6-OHDA
and MPTP have been more extensively used by investigators
to produce PD models despite their limitations.  The
neurotoxin 6-OHDA is a structural analogue of
catecholamines, dopamine and noradrenaline, and exerts its
toxic effects on catecholaminergic neurons4.  Since 6-OHDA
does not penetrate the blood brain barrier in adult rats, it
must be administrated stereotactically into the substantia
nigra or striatum to damage the dopaminergic nigrostriatal
system5, 6.  Recognition of MPTP as a neurotoxin occurred
early in 1982, when several young drug addicts mysteriously
developed a profound Parkinsonian syndrome after
intravenous use of street preparations of meperidine analogs
that, unknown to anyone, were contaminated with MPTP7, 8,
an incidental byproduct during the chemical synthesis of a
meperidine analog (Fig. 1) with potent heroin-like effects7.
MPTP has been found to produce irreversible Parkinsonism
in humans almost indistinguishable from PD8, 9.  It is also
well known that MPTP depletes striatal dopamine and
causes damage to the substantia nigra pars compacta (SNpc)
dopaminergic neurons in non-human primates and several
species of rodents10–13.
Recently, a great deal of interest has been focused on
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stem cell therapies for PD.  In addition to fetal nigral
transplantation, the capability of self-repair in the central
nervous system (CNS) in the adult mammalian has also
given a new perspective in the cell-based approach for
treatment of neurodegenerative disorders.  In PD or its
animal models, much attention has been attracted to whether
the depletion of dopaminergic neurons triggers activation of
neural stem cells and their subsequent migration into the
damaged area, finally resulting in repopulation of
dopaminergic neurons in the SN.  This review will provide
the body of evidence available for endogenous neurogenesis
in response to neurotoxin damage in animal models of PD.
The Origin and Properties of Neural Stem Cells
Neurogenesis continues into adult life in the brains of
rodents14, 15, nonhuman primates16, 17, and humans18, 19.  It is
confined largely to two discrete areas, the subventricular
zone (SVZ) and the subgranular zone (SGZ) of dentate gyrus
(DG)20 (Fig. 2).
The SVZ, located throughout the inner wall of the
lateral ventricle, is the largest germinal region and harbors
neural stem cells that retain the capacity to generate multiple
cell types21.  The SVZ is composed of neural progenitor cells
(migrating neuroblasts, A cells), neural stem cells
(astrocytes, B cells), neural precursor cells (rapidly dividing
transit amplifying cells, C cells) and ependymal cells22–24
(Fig. 2).  Neural stem B cells divide to give rise to clusters of
precursor C cells, which in turn generate neuroblast A
cells23.  Newly generated A cells in the SVZ migrate through
a network of tangential pathways in the lateral wall of the
lateral ventricle and then converge onto the rostral migratory
stream (RMS) to enter the olfactory bulb (OB) via a “chain
migration” behavior25, in which they differentiate into
Fig. 1. MPTP is a byproduct during the chemical synthesis of a
meperidine analog. MPTP neurotoxicity develops only after
metabolization to MPDP+ by MAO-B in glial cells and then to
MPP+, the active toxic compound.
Fig. 2. Schematic representations of the migratory pattern of newly generated A cells in the SVZ (up) and the cell populations in the SGZ of the
DG (bottom left) and SVZ (bottom right) in the adult rodent brain (adapted from Ref. 24).He and Nakayama 103
granule cells and interneurons (Fig. 2)25, 26.  It has been
suggested that Prokineticin 2 (PK2) serves as a
chemoattractant for SVZ-derived neuroblast A cells, which
appears to guide the migration of A cells from the SVZ
through the RMS to their final layers in the OB27.  The
multipotential A cells residing in the SVZ and RMS are
eliminated through apoptosis to maintain a balance for
proper development of the mammalian nervous system28–30.
Metalloproteinases (MMPs) may also play a crucial role in
the migration of individual A cells since their migration rates
are reduced by the presence of inhibitors of MMPs31.  The
architecture and function of the adult human SVZ differs
significantly from that described in other mammals.  There
are four layers of varying thicknesses and cell densities
throughout the lateral ventricular wall: a monolayer of
ependymal cells (Layer I), a hypocellular gap (Layer II), a
ribbon of cells (Layer III) composed of astrocytes and a
transitional zone (Layer IV) into the brain parenchyma32.
The DG is a part of the hippocampal formation.
Neuronal progenitors in the adult mammalian hippocampal
DG reside in the SGZ, which is located in the hilus
immediately beneath the granular layer of the DG33, 34.
Neurogenesis in the DG was first demonstrated 40 years ago
by autoradiography in rodents35 and thereafter was further
demonstrated in all mammalian species including human19
and nonhuman primates36, 37.  Two types of neural
progenitors can be identified in the SGZ according to their
specific morphologies and expression of unique sets of
molecular markers38 (Fig.2).  The primary progenitors (type-
1 cells) have the appearance of radial glia, which also
express glial fibrillary acidic protein (GFAP).  They share
similar features with type the B cells residing in the adult
SVZ and are suggested to be a putative stem cell
population39.  Type-2 cells (intermediate progenitors) are
GFAP-negative and highly proliferative40, sharing similar
features with the neuroblast A cells residing in the adult
SVZ.  Type-2 cells may arise from type 1 cells, but direct
evidence delineating this lineage relationship is still
lacking38.  Newborn type-2 cells disperse and migrate a short
distance into the granule cell layer where they differentiate,
extend axons and express neuronal marker proteins34, 41.  The
migration of newborn neurons in the dentate gyrus may also
be controlled by guidance cues, as these cells only migrate to
the hilus or molecular layer under pathological conditions,
such as in animal models of temporal lobe epilepsy38. 
Dopamine and Neurogenesis
Dopamine plays important roles in many physiological
functions, including motor control, mood and the reward
pathway42, and as a neurotransmitter, it binds to the five
types of dopamine receptor, D1, D2, D3, D4 and D5, and
their variants.  The D1 and D5 receptors are members of the
D1-like family (D1L), whereas the D2, D3 and D4 receptors
are members of the D2-like family (D2L).  It is known that
both PD and neurotoxin-induced PD animal models are
mainly characterized by a hallmark of dopamine depletion.
Furthermore, dopamine replacement therapy is the most
effective treatment for PD to date.  Herein, the involvement
of dopamine in adult neurogenesis is discussed.
Neurogenesis is a key event during both physiological
and pathological processes and is regulated by a variety of
stimuli, such as hormones, intrinsic growth factors,
neurotransmitters, exogenously applied agents,
environmental factors, exercise and age.
Dopamine has been shown to regulate cell cycles in the
developing brain43.  The activation of dopamine receptors
influences cell proliferation in the lateral ganglionic
eminence (LGE) and the neuroepithelium of the frontal
cortex in embryonic mice44, 45.  Dopamine has attracted a lot
of attention concerning the role it plays in adult neurogenesis
in recent years.  In PD animal models, the first thing that
needs to be clarified is whether decreased/increased
neurogenesis is associated with the dopamine-involved
signaling pathway or is a response to destruction of the
nigrostriatal system.
By using immunohistochemical and ultrastrctural
analyses, Höglinger et al. have provided anatomical
evidence that D2L receptors in the SVZ are expressed
predominately on C cells, whereas A cells express both D1L
and D2L receptors in the mouse brain46.  Dopaminergic fiber
has also been confirmed to contact precursor cells in the
SVZs of adult humans and primates46, 47.  Thus, dopamine
seems to play a key role in the regulation of adult
mammalian neurogenesis.  Findings from in vitro
experiments show that activation of the D2L receptor
directly stimulates proliferation of SVZ precursor cells46.
This is supported by a recent study, in which stimulation of
dopamine D2 receptors increased the proliferation of neural
progenitor cells both in vivo and in vitro47.  The depletion of
nigrostriatal dopamine reduces precursor cell production in
the SVZs of mice and aged primates and further leads to
impaired neurogenesis in the OB46, 47.  Based on the finding
that acute administration of SCH23390, a D1 receptor
antagonist, reduces the number of 5’-bromodeoxyuridine
(BrdU)-positive cells in the SGZ of the DG, Suzuki et al.
suggest that adult neurogenesis in the DG may be regulated
naturally by dopamine via D1-like receptors48.  A very recent
report demonstrated that dopamine regulates adult
neurogenesis by a mechanism of modulating ciliary
neurotrophic factor (CNTF) expression in SVZ astrocytes49.
The findings of Van Kampen et al. indicate that
administration of the dopamine D3 receptor agonist, 7-
hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT),
significantly increases the proliferation of neural stem cells
(NSCs) in the adult rat brain50, 51 but not in the adult mouse
brain51.  Furthermore, chronic intraventricular
administration of 7-OH-DPAT triggers a profound induction
of cell proliferation in the rat SN and promotes adoption of a
neuronal phenotype in some of these newly generated cells52.
On the other hand, it has been suggested that treatment
with 7-OH-DPAT does not affect the proliferation, survival
or neurogenesis of murine and human neural progenitor cells
derived from the fetal midbrain in vitro53.  Moreover,104 Neurogenesis in PD Animal Models
chronic treatment with the antipsychotic drug haloperidol
leads to increased NSC numbers, resulting in more
progenitors and more new neurons and glia in the adult rat
brain due to a mechanism of antagonizing dopamine at the
D2 receptors on NSCs54.  Treatment with haloperidol also
increases dentate granule cell proliferation in the gerbil
hippocampus55, 56.  These controversial data question the
involvement of dopamine in adult neurogenesis.
Neurogenesis in MPTP Animal Models for PD
MPTP neurotoxicity develops only after metabolization
to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) by
an enzyme, monoamine oxidase (MAO)-B, and further to 1-
Methyl-4-phenylpyridinium (MPP+), the active toxic
compound (Fig. 1)7.  Since MPP+ is selectively transported
into presynaptic dopaminergic nerve terminals through the
dopamine transporter (DAT)57–61 and the absence of the DAT
on dopaminergic neurons confers complete protection
against MPTP toxicity59, 60, the neurotoxicity of MPTP is
suggested to be selective to dopaminergic neurons in the SN.
MPTP is mainly used in non-human primates and rodents62,
63, and the latter are less sensitive to MPTP neurotoxicity64.
In rodents, C57BL/6 mice have been used in a great deal of
reports for creation of a PD animal model for understanding
the disease pathogenesis, despite their limitions.
Zhao et al. first provided morphological evidence that
administration of MPTP leads to a 2-fold increase of BrdU
incorporation in nigral dopaminergic neurons65.  Newly
generated dopaminergic neurons has been demonstrated to
be derived from the cells lining the ventricular system65.  By
using the nestin second intron enhancer-controlled LacZ
reporter transgenic mouse model coupled with the MPTP
lesion system, Shan et al. demonstrated that there is
increased dopaminergic neurogenesis in the SN66,
supporting the findings of Zhao et al. as described above.  In
rat and macaque monkey hemi-Parkinsonian models treated
stereotatically with MPP+, the dopamine-depleted
hemisphere showed more polysialic acid (PSA)-positive
cells, candidates for newly differentiated young neurons,
than the intact side, and a small number of tyrosine
hydroxylase (TH)-positive cells were demonstrated to be
PSA-positive67.
In the striatum of the MPTP-treated aged macaque,
although there is an increase in the number of TH-
immunoreactive neurons, the increase has been suggested to
be derived from pre-existing GABAergic interneurons
(phenotype shift), not neurogenesis68.  Yamada et al.69
performed a retroviral vector-based method to evaluate
neurogenesis in the OBs of MPTP-treated mice, and the
results showed that dopaminergic neurogenesis can be
enhanced in the OB after dopaminergic neuron loss.
However, their findings do not clearly indicate relevance to
the damaged nigrostriatal system.  Increased neurogenesis
has also been confirmed in a very recent paper70, in which
MPTP lesions increased the incorporation of BrdU as well as
the number of cells that co-expressed BrdU and the
immature neuronal marker doublecortin (DCX) in the DG,
SVZ and striatum, but not in the SN of the MPTP-treated
mouse, although the differentiation of newly generated cells
into dopaminergic neurons was not investigated.
On the other hand, decreased neurogenesis has also
been demonstrated in MPTP animals.  Höglinger et al.
demonstrated that proliferation of transit amplifying cells (C
cells) is impaired in the SVZ and SGZ in the MPTP mouse
model for PD46.  C cells are the target of a dopaminergic
innervations, and impaired neurogenesis in the SVZ is thus
suggested to be mediated by MPTP administration-induced
dopamine depletion46.  Furthermore, reduced C cells lead to
a subsequent decrease in A cells46.  In adult macaques,
MPTP-induced dopamine depletion also results in decreases
in the number of proliferating cell nuclear antigen-positive
(PCNA) cells and A cells in the SVZ47, suggesting that intact
dopaminergic nigro-subventricular innervation is crucial for
sustained neurogenesis in aged primates47.
In recent years, the selective neurotoxicity of MPTP in
the dopaminergic system of the adult brain has been
challenged.  A number of studies71–73 have demonstrated that
MPTP also destroys forebrain migrating neuroblasts and
nigrostriatal glial cells (astrocytes) in the adult mouse brain.
In our previous studies72, 73, the number of apoptotic cells in
the SVZ and RMS peaked at 24 hours after MPTP injections
and decreased thereafter, paralleling the changes in number
of cleaved caspase-3-positive cells.  The cells undergoing
apoptosis in the SVZ, RMS and OB were identified as A
cells using immunohistochemistry and ultrastructural
analyses, while a few were astrocytes (B cells), and none
were transit-amplifying procursors (C cells)72, 73.  The
decrease in A cell numbers was most marked on day 2 and
lasted to day 8 after administration72, 73.  We also
demonstrated that MAO-B inhibitors, such as deprenyl or N-
(2-aminoethyl)-4-chlorobenzamide (Ro 16-6491)
completely protected A cells against MPTP neurotoxicity,
suggesting that MPTP neurotoxicity in A cells is also
mediated by the conversion of MPTP into MPP+ by MAO-
B74.
A cells are main populations in the SVZ and RMS of
the adult brain, and proliferation of A cells may contribute to
dult endogenous neurogenesis.  Using BrdU labeling, we
provided evidence that MPTP injury leads to transiently
impaired neurogenesis in the adult mouse SVZ and OB.  The
majority of BrdU-positive cells in the SVZ are rapidly
depleted by MPTP, and only a few BrdU-positive cells
migrate into the OB thereafter (Fig. 3).  Thus, impaired
neurogenesis is more likely to be due to an MPTP-induced
decrease in A cells rather than a mechanism through
dopamine depletion as reported in previous studies46, 47.
Impaired neurogenesis persists for about two weeks in
the MPTP-injured mouse brain and is followed by
recruitment of cells in the SVZ (He et al., unpublished data).
The self-repairing process for the damaged germinal region
is evidenced by regeneration of A cells (He et al.,
unpublished data).  Thus, neurogenesis in the nigrostriatal
system in response to MPTP damage, if it does occur, mayHe and Nakayama 105
be a later event in the self-repairing process of the injured
SVZ.  In a recent study70, increases in BrdU-positive cells
and BrdU-Dcx double-labeled cells in the SVZ were
observed 14 d after acute MPTP treatment.  This, however,
may have been due to an activated self-repairing process in
the SVZ rather than a response to nigrostriatal damage.
Neurogenesis in 6-OHDA Animal Models for PD
Since 6-OHDA does not penetrate the blood brain
barrier in adults, it must be administrated stereotactically
into the substantia nigra or striatum to damage the
dopaminergic nigrostriatal system5, 6.  Although
administration of 6-OHDA produces a decreased striatal
dopamine level and loss of dopaminergic neurons in the SN
in the adult brain, the 6-OHDA model does not mimic any
clinical or pathological features of PD.  In adult rats, when
the right mesencephalic dopaminergic neurons are ablated
by stereotactical injection of 6-OHDA into the right
nigrostriatal pathway, the number of PCNA-positive cells in
the SVZ ipsilateral to the lesion decreases46.  Impaired
proliferation of cells in the SVZ has also been suggested to
be mediated by a mechanism of dopamine depletion as
suggested in MPTP animals46.  Evidence from C57BL/6
mice injected unilaterally with 6-OHDA into the midbrain
part of the medial forebrain bundle also show impaired
neurogenesis, and 6-OHDA-induced dopaminergic
denervation of the striatum reduces CNTF mRNA levels in
the SVZ, which further contributes to negative regulation of
the proliferation of cells49.
Although the proliferation of NSCs in the SVZ and DG
in the adult brain is an important neurogenesis process and
has been demonstrated in some neurodegenerative diseases,
it remains controversial whether those proliferated NSCs
migrate into the damaged area and repopulate the lost
functional neurons.
Treatment of 6-OHDA also leads to a transient decrease
in neurogenesis in the olfactory granule cell layer, but, in
contrast, an increase of neurogenesis is present in the
glomerular layer75.  The increased neurogenesis in the
glomerular layer is characterized by more newly generated
neuronal nuclear antigen (NeuN)- and TH-expressing
neurons, indicating a shift in cell fate decision for newly
generated neuronal precursors targeted at the glomerular
layer75.
Frielingsdorf et al. detected increases in cell
proliferation in the SN in rats injected with 6-OHDA into the
median forebrain bundle; however, none of the newly born
cells expressed a dopaminergic phenotype, and there is no
evidence of neural stem cells emanating from the
cerebroventricular system and migrating to the substantia
nigra76.  Growth factors, such as platelet-derived growth
factor (PDGF-BB) and brain-derived neurotrophic factor
(BDNF), can induce striatal neurogenesis in adult rats with
6-OHDA lesions, and there are no indications of any newly
born cells differentiating into dopaminergic neurons
following growth factor treatment both in the striatum and in
the SN75.  Surprisingly, in a salamander 6-OHDA model for
PD, robust and complete regeneration of the mesencephalic
and diencephalic dopamine system occurs after elimination
of dopaminergic neurons77.  This regeneration leads to
histological restoration and full recovery of motor
behavior77.  This 6-OHDA salamander model gives new
insight into the animal models for PD and may be helpful for
understanding the molecular mechanism of dopaminergic
neurogenesis.
The findings of Steiner et al.  indicate that the absolute
numbers of newborn cells in the SN are not affected by
dopamine depletion in the 6-OHDA rat model for PD.
Instead, 6-OHDA lesions induce a specific downregulation
of generation of newborn nigral astrocytic cells78.
Conclusion
The replacement of lost neurons in a damaged brain
area is the best direction for therapeutic development in
relation to neurodegenerative diseases.  Based on all of the
available evidence, neurogenesis is still a most controversial
issue in studies of neurodegenerative diseases and their
animal models.  In MPTP animal models for PD, we have
demonstrated that MPTP destroys A cells in the SVZ and
OB in the adult brain and then transiently impairs
neurogenesis; however, it remains to be investigated whether
and how multiple potential neural stem cells migrate into the
nigrostriatal system and replace the lost dopaminergic
neurons.  With increased attention to dopaminergic
neurogenesis in neurotoxin-induced animal models for PD, it
is expected that the models will become useful as tools for
understanding the mechanisms for neurogenesis in PD and
that many questions regarding neurogenesis in
Fig. 3. MPTP reduces the number of BrdU+ cells in the SVZ and OB.
The majority of BrdU-positive cells in the SVZ are rapidly
depleted at 2 days, and only few BrdU-positive cells migrate
into the OB at 7 days after MPTP administration.106 Neurogenesis in PD Animal Models
neurodegenerative diseases will be resolved.
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